Drug intelligence / Profile preview

MABS-139

Development stage: Unknown
Lead developer: Manhattan Biosolutions
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes

Overview

**MABS-139** is the lead program from Manhattan BioSolutions, a rationally designed **RNA-degrading protein** engineered to exhibit broad anti-tumor efficacy across preclinical animal models of solid tumors. It targets RNA modulation to disrupt tumor cell processes, demonstrating promising safety and pharmacokinetics in a completed Phase 1 dose-escalation study.[1][4][9]

Beyond the preview

Go deeper on MABS-139.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MABS-139.

Explore the full profile